Balaji Gandhi Sells 8,045 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 8,045 shares of Phreesia stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total value of $191,873.25. Following the completion of the transaction, the chief financial officer now owns 108,411 shares of the company’s stock, valued at approximately $2,585,602.35. The trade was a 6.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Balaji Gandhi also recently made the following trade(s):

• On Wednesday, March 26th, Balaji Gandhi sold 1,827 shares of Phreesia stock. The shares were sold at an average price of $27.46, for a total value of $50,169.42.
• On Tuesday, February 18th, Balaji Gandhi sold 5,771 shares of Phreesia stock. The stock was sold at an average price of $30.04, for a total value of $173,360.84.
• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total transaction of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total transaction of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The shares were sold at an average price of $27.31, for a total transaction of $159,135.37.
• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $22,555.28.

Phreesia Stock Up 0.3 %

NYSE PHR opened at $24.06 on Friday. The company has a market capitalization of $1.41 billion, a P/E ratio of -16.37 and a beta of 0.82. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $30.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The company’s 50 day simple moving average is $26.57 and its 200 day simple moving average is $24.26.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PHR shares. Needham & Company LLC reissued a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a report on Thursday, March 13th. Piper Sandler reissued an “overweight” rating and issued a $33.00 price target (up previously from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Citigroup increased their target price on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Finally, Canaccord Genuity Group boosted their price target on shares of Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia presently has an average rating of “Buy” and a consensus price target of $31.33.

Institutional Investors Weigh In On Phreesia

Institutional investors and hedge funds have recently modified their holdings of the stock. Rhumbline Advisers raised its position in shares of Phreesia by 3.8% during the first quarter. Rhumbline Advisers now owns 86,844 shares of the company’s stock worth $2,220,000 after purchasing an additional 3,213 shares during the period. GAMMA Investing LLC raised its holdings in Phreesia by 10,605.7% during the 1st quarter. GAMMA Investing LLC now owns 5,674 shares of the company’s stock worth $145,000 after buying an additional 5,621 shares during the period. Probity Advisors Inc. purchased a new stake in Phreesia during the fourth quarter valued at about $304,000. PharVision Advisers LLC purchased a new stake in Phreesia during the fourth quarter valued at about $302,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Phreesia in the fourth quarter worth about $302,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.